kg9999
NoneThe last time I looked, the Stanley Cup was still won in June and not November. That’s why I find it puzzling that a well-respected hockey pundit such as Craig Button could make made such a bold statement that in his mind the Edmonton Oilers don’t have a team good enough to contend for the Stanley Cup. Button made this statement recently on Sportsnet with Jay Onrait and mentioned that, “they (the Edmonton Oilers) don’t have enough good players to be Stanley Cup contenders...that’s the bottom line.” These comments came on the heels of one the Oilers 3-0 loss to the Montreal Canadiens on Nov. 18 – one of the Oilers worst performances of the season. The Oilers bounced back the next night with a 5-2 thumping of the Ottawa Senators to make their three-game eastern Canadian road swing look somewhat respectable. There’s a lot of hockey to be played between now and the beginning of the playoffs, and despite the Oilers somewhat-slow start to the season, I would respectfully counter Button’s commentary by saying that there are a few factors that still make the Oilers a team to watch out for in the NHL’s Western Conference. Oilers Have Key Players on the Injured List The Oilers sick bay is starting to pile up with Viktor Arvidsson and Zach Hyman out day to day, Darnell Nurse out until late November and Evander Kane on long term injured reserve (LTIR) after preseason hip surgery. Kane is a key factor for the Oilers as he will not only add a sorely-missed physical presence to the lineup when he returns, but if remains on LTIR until the playoffs, the Oilers could possibly add another impact player at the March 8 NHL Trade Deadline. They would have to take a page out of the Vegas Golden Knights’ LTIR playbook, where veteran forward Mark Stone has returned from LTIR just in time for the playoffs the last past three seasons. This point about LTIR and Kane’s eventual return signifies that the Oilers roster is still a work in progress, and I would see how the team is doing in late March and early April before saying whether they’re Stanley Cup contenders or not. Improvements To Oilers’ Defence Will Come It’s no secret the Oilers are looking for help on the back end. In a recent interview on Oilers Now , former NHL general manager (GM) Brian Lawton told host Bob Stauffer that there’s room for improvement on the blue line that could help the goaltenders. They discussed the possibility of the Oilers hitting the jackpot in a similar fashion to how they did when trading for Mattias Ekholm in 2022-23. Can lightning strike twice for the Oilers? There’s a lot of pressure on Oilers GM Stan Bowman to bring in a top-four defenceman. Right now the Oilers are relying on Ekholm, Evan Bouchard, Brett Kulak, Travis Dermott, Ty Emberson and Troy Stecher to carry the load. Bouchard looks as though he’s emerging from his early-season slump and it looks like the Oilers have an emerging d-man in Emberson, so the sky isn’t completely falling right now. However, they could still use another proven defenceman for a drive to the playoffs. Oilers Forward Group Hasn’t Found Their Stride Yet The Oilers seem to be front end loaded but the reality is Connor McDavid and Leon Draisaitl are currently carrying the team. Ryan Nugent-Hopkins, Zach Hyman, Jeff Skinner and Arvidsson are all under performing. There’s still a lot of runway left in the season for this group of forwards to turn things around. It might be wise for the coaching staff to give Skinner more time on the top two lines. He’s a proven goalscorer and point producer, and needs an opportunity to gel and find some chemistry with some line mates. Once that happens, the floodgates could open. Goaltending Will Improve Many fans are screaming for the Oilers to go out and get a Dominik Hasek type of goalie who can win games by himself. But top-end goalies don’t come cheap and the Oilers are tight against the salary cap. Is there a cheap Chris Osgood type goalie who performs well within the system established, or do the Oilers already have that in the duo of Stuart Skinner and Calvin Pickard? Unless Bowman can fleece another team for a top-end goalie with salary retained, the Oilers will drive towards the postseason with Skinner and Pickard. Skinner especially needs to pick up his game, and he is capable of doing that. He’s still the guy that out-dueled Dallas Stars starter Jake Oettinger in the Western Conference Final last season. He just hasn’t found his game yet, but seems to have the talent and mental capacity to improve. Meanwhile Pickard, though not flashy, is still reliable. It’ll be interesting to see whether Bowman makes a move for a goaltender on or before the trade deadline. Oilers Currently in Contention in the Pacific Division It seems like nobody is running away with the Pacific Division. As of Nov. 21, the Oilers are just two points back of the division leading Golden Knights and are right in the thick of things after 20 games. The Oilers have a history of having a strong second half to the season and if they can stay with the pack in the Pacific over the next two months, they could have a legitimate shot at winning it. They are also currently only two points back of the Dallas Stars in the NHL’s Western Conference, and despite the strong start from both the Minnesota Wild and league-leading Winnipeg Jets, you just never know where things will land once winter turns to spring. It’s really hard to make predictions and look into the future. I don’t take much stock in the pre-season Stanley Cup predictions. They’re fun for fans and good for debate, but there are so many things that happen in a long NHL season. Right now the Jets look like the team to beat in the NHL but the playoffs can be a different animal. That’s why I wouldn’t count out a battle-hardened team like the Oilers to make some noise once the postseason comes. After all, they still have McDavid and Draisaitl on their roster and that alone can make all the difference. This article first appeared on The Hockey Writers and was syndicated with permission.
The Latest: Police believe gunman who killed UnitedHealthcare CEO has left New York CityKey Automotive Tire Market Trend 2024-2033: Pressure Sensor TechnologyMENLO PARK, Calif. , Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA , on January 14, 2025 . BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years. This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows: Location: Mission Bay (32nd Floor) at The Westin Date: Tuesday, January 14, 2025 Time: 2:30-2:55 pm PT A webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/ About BillionToOne Headquartered in Menlo Park, California , BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone. The company's patented Quantitative Counting TechnologyTM (QCTTM) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/billiontoone-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302338634.html SOURCE BillionToOne
AP News Summary at 3:19 p.m. ESTClosing the gap in overseas remittances for FilipinosOttawa driver hits the road impaired despite winter driving conditions: OPP
Burt, the huge Australian crocodile who had a cameo in ‘Crocodile Dundee,’ dies at 90Soccer-Portugal winger Nani announces retirementComing to a theater near you: How cinema screens may soon become gigantic LED displays thanks to a plethora of Chinese companies looking for new markets
EAST LANSING, Mich. — The sight was a common one for Andrew Kolpacki. For many a Sunday, he would watch NFL games on TV and see quarterbacks putting their hands on their helmets, desperately trying to hear the play call from the sideline or booth as tens of thousands of fans screamed at the tops of their lungs. When the NCAA's playing rules oversight committee this past spring approved the use of coach-to-player helmet communications in games for the 2024 season, Kolpacki, Michigan State's head football equipment manager, knew the Spartans' QBs and linebackers were going to have a problem. "There had to be some sort of solution," he said. As it turns out, there was. And it was right across the street. Kolpacki reached out to Tamara Reid Bush, a mechanical engineering professor who not only heads the school's Biomechanical Design Research Laboratory but also is a football season ticket-holder. Kolpacki "showed me some photos and said that other teams had just put duct tape inside the (earhole), and he asked me, 'Do you think we can do anything better than duct tape,?" Bush said. "And I said, 'Oh, absolutely.'" Bush and Rylie DuBois, a sophomore biosystems engineering major and undergraduate research assistant at the lab, set out to produce earhole inserts made from polylactic acid, a bio-based plastic, using a 3D printer. Part of the challenge was accounting for the earhole sizes and shapes that vary depending on helmet style. Once the season got underway with a Friday night home game against Florida Atlantic on Aug. 30, the helmets of starting quarterback Aidan Chiles and linebacker Jordan Turner were outfitted with the inserts, which helped mitigate crowd noise. DuBois attended the game, sitting in the student section. "I felt such a strong sense of accomplishment and pride," DuBois said. "And I told all my friends around me about how I designed what they were wearing on the field." All told, Bush and DuBois have produced around 180 sets of the inserts, a number that grew in part due to the variety of helmet designs and colors that are available to be worn by Spartan players any given Saturday. Plus, the engineering folks have been fine-tuning their design throughout the season. Dozens of Bowl Subdivision programs are doing something similar. In many cases, they're getting 3D-printed earhole covers from XO Armor Technologies, which provides on-site, on-demand 3D printing of athletic wearables. The Auburn, Alabama-based company has donated its version of the earhole covers to the equipment managers of programs ranging from Georgia and Clemson to Boise State and Arizona State in the hope the schools would consider doing business with XO Armor in the future, said Jeff Klosterman, vice president of business development. XO Armor first was approached by the Houston Texans at the end of last season about creating something to assist quarterback C.J. Stroud in better hearing play calls delivered to his helmet during road games. XO Armor worked on a solution and had completed one when it received another inquiry: Ohio State, which had heard Michigan State was moving forward with helmet inserts, wondered if XO Armor had anything in the works. "We kind of just did this as a one-off favor to the Texans and honestly didn't forecast it becoming our viral moment in college football," Klosterman said. "We've now got about 60 teams across college football and the NFL wearing our sound-deadening earhole covers every weekend." The rules state that only one player for each team is permitted to be in communication with coaches while on the field. For the Spartans, it's typically Chiles on offense and Turner on defense. Turner prefers to have an insert in both earholes, but Chiles has asked that the insert be used in only one on his helmet. Chiles "likes to be able to feel like he has some sort of outward exposure," Kolpacki said. Exposure is something the sophomore signal-caller from Long Beach, California, had in away games against Michigan and Oregon this season. Michigan Stadium welcomed 110,000-plus fans for the Oct. 26 matchup between the in-state rivals. And while just under 60,000 packed Autzen Stadium in Eugene, Oregon, for the Ducks' 31-10 win over Michigan State three weeks earlier, it was plenty loud. "The Big Ten has some pretty impressive venues," Kolpacki said. "It can be just deafening," he said. "That's what those fans are there for is to create havoc and make it difficult for coaches to get a play call off." Something that is a bit easier to handle thanks to Bush and her team. She called the inserts a "win-win-win" for everyone. "It's exciting for me to work with athletics and the football team," she said. "I think it's really exciting for our students as well to take what they've learned and develop and design something and see it being used and executed." Be the first to know Get local news delivered to your inbox!
AP Business SummaryBrief at 6:23 p.m. EST
KFC S'pore bringing back parmesan truffle chicken, launching caramel mochi rings more on Nov. 27Snap: 25 Million Reasons To LoveLebanon said Israeli strikes Thursday on the country's east and south killed 52 people, as raids also hit south Beirut and Hezbollah claimed its deepest attack on Israel in over a year. More than 11 months of cross-border fire between Israel and Hezbollah over the Gaza conflict escalated into all-out war in September, with Israel conducting an extensive bombing campaign, primarily targeting Hezbollah strongholds, and sending ground troops into southern Lebanon. "Israeli enemy strikes that targeted the Baalbek district" in east Lebanon's Bekaa Valley left "40 dead and 52 wounded", a health ministry statement said, listing tolls for 10 different locations. Lebanon's official National News Agency (NNA) said a couple and their four children were killed in a strike on a house in the village of Maqneh, while another couple and their young daughter were among 11 people killed in a raid on nearby Nabha. The ministry also reported "seven dead and 24 wounded" in "Israeli enemy strikes" on south Lebanon's Nabatiyeh district, and "five dead and 26 wounded" in strikes elsewhere in south Lebanon. In Israel, first responders said a man was killed after rocket fire from Lebanon hit the Galilee region in the country's north. In Beirut's southern suburbs, the NNA reported at least 12 strikes throughout Thursday, after relative calm while US envoy Amos Hochstein visited earlier this week, seeking to broker an end to the Israel-Hezbollah war. Israeli army spokesman Avichay Adraee on social media platform X issued several rounds of evacuation warnings for Beirut's southern suburbs, as well as areas in and around the southern coastal city of Tyre, but none for east Lebanon. AFPTV footage showed columns of smoke rising from the southern suburbs, usually a densely populated residential district but now largely emptied. Adraee said on X that the Israeli military "targeted a weapons depot, a command headquarters and terrorist infrastructure" belonging to Hezbollah in south Beirut. Amid a series of attack claims, Hezbollah said its fighters targeted "the Hatzor air base" near Israel's southern city of Ashdod, around 150 kilometres (90 miles) from Lebanon's southern border, "with a missile salvo" -- its deepest target in more than a year of hostilities. In 10 separate statements, Iran-backed Hezbollah said its fighters also targeted Israeli troops in and near the south Lebanon town of Khiam, including with artillery, rockets and drones. The NNA said "the enemy army" was "blowing up homes and residential buildings during its incursion into the town". Lebanon's official news agency and Hezbollah have reported fighting and air strikes in the Khiam area ever since Israeli ground troops first entered Lebanon on September 30. Earlier Thursday, United Nations special coordinator for Lebanon Jeanine Hennis-Plasschaert visited Baalbek's UNESCO-listed archaeological area, after the UN's cultural body this week granted more than 30 heritage sites in Lebanon "provisional enhanced protection" amid the war. Lebanon's health ministry said Thursday that at least 3,583 people had been killed in the violence since October 2023. Most of the deaths have been since September this year. The Israeli military said Wednesday that three soldiers were killed in south Lebanon, bringing to 52 the number killed in Lebanon since the start of ground operations. bur-lg/giv
Cayuga County real estate: See all homes sold, Nov. 30-Dec. 6
None
AP Trending SummaryBrief at 3:36 p.m. ESTVolvo Cars Australia hasn’t given up on its trusty XC90 just yet, with the popular large SUV’s second facelift originally not intended for our market now confirmed for launch during the first half of 2025. Revealed in September, the 2025 Volvo XC90 is the third iteration of the second-generation model first launched globally in 2015, boasting a more comprehensive set of design revisions and Volvo’s latest technologies to bring it in line with the Swedish brand’s newest models like the all-electric EX90 . Headlining the changes are a new face more akin to Volvo’s new electric range of ‘EX’ models, as well as a new 11.2-inch high-resolution infotainment system running the brand’s latest interface. Know the news with the 7NEWS app: Download today Volvo has applied some less obvious changes, like improved storage space in the centre console, a relocated wireless smartphone charger, redesigned gear selector and additional sound insulation to make the cabin quieter. 100s of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now . Beyond that, “the best-ever Volvo XC90” is more or less the same under the skin – and it already had proven and capable underpinnings. Volvo is keen to label the available T8 plug-in hybrid version as an “electric car with a back-up plan”, quoting over 70km of WLTP-certified electric driving range, and a further 800km of range from the turbocharged petrol engine (based on fuel economy of 8.6L/100km once the battery is depleted). Globally, the existing B5 and B6 mild-hybrid versions also carry over. It’s unclear if all three powertrain variants will continue in Australia into 2025, or whether the T8 will become more widely available. Full pricing and specifications for our market will be detailed closer to launch but, for reference, the existing range is priced from $99,940 plus on-road costs for the Ultra B5 Bright, climbing to $128,390 before on-roads for the Ultra T8 Plug-in Hybrid flagship. Given the expected upgrades, we could see the upgraded XC90’s starting price in Australia start above six figures, unless base pricing reduces closer to the $86,990 entry point from a few years ago when the more affordable Momentum grade was offered (which could be called Plus in today’s nomenclature). Stay tuned to CarExpert for more details. MORE: 2025 Volvo XC90 gets new lease on life MORE: Everything Volvo XC90NEWARK, Del, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The meningococcal vaccine market is poised for substantial growth from 2024 to 2034. With an initial valuation of USD 3,950.2 million in 2024 , the market is projected to achieve an impressive USD 9,014 million by 2034 , reflecting a compound annual growth rate (CAGR) of 8.6% . This growth is driven by increasing vaccination initiatives, the rising incidence of meningococcal infections, and the global emphasis on preventive healthcare measures. Demand for meningococcal vaccines is increasing due to heightened awareness of meningitis outbreaks and the availability of conjugate and multivalent vaccines. Government-backed immunization programs and mandates for vaccination in schools and universities are further driving market demand, especially in regions with significant disease burdens. Technological advancements are playing a pivotal role, with pharmaceutical companies developing improved, multivalent vaccines that cover more meningococcal serogroups. These vaccines offer broader protection, enhancing global acceptance and uptake. Major players in the market are engaged in partnerships and licensing agreements to boost production capacities and meet surging demand. However, the high cost of meningococcal vaccines and supply chain disruptions present challenges. Despite this, the growing involvement of health organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance, to promote meningitis prevention in low-income regions is expected to bridge these gaps, ensuring sustained market growth over the next decade. Get Full Report Now - Country-wise Insights The section presents a regional study of the worldwide meningococcal vaccination market in the near future. According to these figures, Western countries such as the United States and the United Kingdom are quite likely to see strong development during the next ten years. China is also one of the most profitable countries in this sector in Asia. Key Takeaways from the Market Study "The Meningococcal Vaccine Market is on a robust growth trajectory due to the confluence of strong government mandates, rising public health awareness, and ongoing R&D efforts. The market's growth is further supported by international vaccination programs in lower-income regions and the introduction of multivalent vaccines, which provide wider protection. With an 8.6% CAGR expected over the next decade, stakeholders should focus on capacity expansion, technological advancement, and partnerships with health organizations to drive sustainable growth," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) Key Market Insights Rising Incidence of Meningococcal Disease : In 2019, there were approximately 2.51 million cases of meningitis globally, with a notable number of cases occurring in children under five years old. This alarming prevalence has heightened public concern and increased vaccination efforts. Growing Awareness : There is an increasing awareness among healthcare professionals and the general public about the seriousness of meningococcal disease, which is contributing to higher vaccination rates. Government Initiatives : Many countries have implemented national immunization programs targeting infants, adolescents, and young adults to curb the incidence of meningococcal disease. These initiatives are crucial in driving market growth. Advancements in Vaccine Development : Ongoing advancements in vaccine technology are leading to the development of more effective meningococcal vaccines that provide broader protection against multiple strains and require fewer doses. Healthcare Infrastructure : Countries with well-established healthcare systems, such as the United States and the United Kingdom, are seeing a trend towards increased vaccination against meningococcal disease. Conjugate vaccines play a crucial role in the meningococcal vaccine market by providing effective and long-lasting protection against meningococcal disease, which is caused by the bacterium Neisseria meningitides. Here are the key contributions of conjugate vaccines to the market: Key Contributions of Conjugate Vaccines Regional Analysis of Meningococcal Vaccine Market Competition Outlook The competitive landscape of the global meningococcal vaccine market is primarily driven by innovations in vaccine formulations. The consumer base of the company in the industry totally depends on the efficiency, cost, and safety profile of the vaccine they formulate. Companies are also tying up with government and international organizations to expand their market reach and ensure wider vaccine accessibility. Industry Updates Leading Meningococcal Vaccines Brands Key Segments of Market Report On the basis of product type: The sector is bifurcated into polysaccharides and conjugates. Based on the age group: The industry is segmented into infants, children, adolescents, young adults, and adults. On account of end users: The sector is segmented into, pharmacies, community, clinics, public health agencies, and others. As per region: The industry is divided into North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa Author by Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore FMI's Extensive Coverage in the Healthcare Domain: The global Meningococcal Meningitis treatment market garnered a market value of USD 170.75 Million in 2022 and is expected to accumulate a market value of USD 283 Million by registering a CAGR of 4.7% The veterinary vaccines market is estimated to reach USD 9,433.9 million in 2024. It is estimated that revenue will increase at a CAGR of 5.2% between 2024 and 2034. The industry is anticipated to reach USD 15,632.4 million by 2034. The livestock vaccine market is predicted to be valued at USD 6.1 billion in 2024 and rise to USD 11.2 billion by 2034. The market is expected to grow at a CAGR of 6.2% during the forecast period. The paediatric vaccine market valuation is USD 54,130.1 million in 2023. The market is predicted to grow at a remarkable CAGR of 13.1% to reach a valuation of USD 184,706.7 million by 2033. The global anti-infective vaccines market was valued at around USD 51.0 Billion at the end of 2021. The market is projected to register a 12.3% CAGR and top a valuation of USD 168.7 Billion by 2032. The vaccines market is likely to strengthen its boundaries at an average CAGR of 6.6% during the forecast period. The market is expected to hold a value of USD 42.7 billion in 2023 Demand for hospital capacity management solutions in Europe is projected to rise at a CAGR of 4.30% through 2033. The global Hospital Workforce Management Market is expected to be valued at USD 1,533.2 million in 2023. The non-hospital-based point-of-care diagnostic products market is likely to rise to a USD 12.9 billion valuation in 2022. The global demand for hospital supplies is expected to increase at 3.7% CAGR over the forecast period from 2022 to 2032. Explore the latest news on Clinical Information Systems Market Outlook 2024-2034 About Future Market Insights (FMI) Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise. Contact Us Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USA T: +1-347-918-3531 For Sales Enquiries: ... Website: LinkedIn | Twitter | Blogs | YouTube GERMAN Translation - Der Markt für Meningokokken-Impfstoffe wird von 2024 bis 2034 voraussichtlich stark wachsen. Bei einer anfänglichen Bewertung von 3.950,2 Millionen USD im Jahr 2024 wird erwartet, dass der Markt bis 2034 beeindruckende 9.014 Millionen USD erreicht, was einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 8,6 % entspricht . Dieses Wachstum wird durch zunehmende Impfinitiativen, die steigende Inzidenz von Meningokokken-Infektionen und den weltweiten Schwerpunkt auf präventive Gesundheitsmaßnahmen vorangetrieben. Die Nachfrage nach Meningokokken-Impfstoffen steigt aufgrund des gestiegenen Bewusstseins für Meningitis-Ausbrüche und der Verfügbarkeit von konjugierten und multivalenten Impfstoffen. Staatlich geförderte Immunisierungsprogramme und Impfpflichten in Schulen und Universitäten treiben die Marktnachfrage zusätzlich an, insbesondere in Regionen mit einer erheblichen Krankheitslast. Technologische Fortschritte spielen eine entscheidende Rolle. Pharmaunternehmen entwickeln verbesserte, multivalente Impfstoffe , die mehr Meningokokken-Serogruppen abdecken. Diese Impfstoffe bieten einen breiteren Schutz und fördern die weltweite Akzeptanz und Nutzung. Wichtige Marktteilnehmer sind Partnerschaften und Lizenzvereinbarungen eingegangen, um die Produktionskapazitäten zu steigern und die steigende Nachfrage zu decken. Die hohen Kosten von Meningokokken-Impfstoffen und Unterbrechungen der Lieferketten stellen jedoch Herausforderungen dar. Dennoch ist zu erwarten, dass das zunehmende Engagement von Gesundheitsorganisationen wie der Weltgesundheitsorganisation (WHO) und der Impfallianz Gavi zur Förderung der Meningitis-Prävention in einkommensschwachen Regionen diese Lücken schließen und so ein nachhaltiges Marktwachstum im nächsten Jahrzehnt sicherstellen wird. Wichtige Erkenntnisse aus der Marktstudie „Der Markt für Meningokokken-Impfstoffe befindet sich aufgrund des Zusammentreffens strenger staatlicher Auflagen, eines steigenden öffentlichen Gesundheitsbewusstseins und laufender Forschungs- und Entwicklungsanstrengungen auf einem robusten Wachstumskurs. Das Wachstum des Marktes wird zusätzlich durch internationale Impfprogramme in einkommensschwächeren Regionen und die Einführung multivalenter Impfstoffe unterstützt, die einen breiteren Schutz bieten. Da für das nächste Jahrzehnt eine durchschnittliche jährliche Wachstumsrate von 8,6 % erwartet wird, sollten sich die Beteiligten auf Kapazitätserweiterung, technologischen Fortschritt und Partnerschaften mit Gesundheitsorganisationen konzentrieren, um nachhaltiges Wachstum voranzutreiben“, sagtSabyasachi Ghosh (Associate Vice President bei Future Market Insights, Inc.). Wichtige Markteinblicke Steigende Inzidenz von Meningokokken-Erkrankungen : Im Jahr 2019 gab es weltweit etwa 2,51 Millionen Meningitis-Fälle, wobei eine bemerkenswerte Zahl von Fällen bei Kindern unter fünf Jahren auftrat. Diese alarmierende Prävalenz hat die öffentliche Besorgnis verstärkt und die Impfbemühungen verstärkt. Wachsendes Bewusstsein : Das Bewusstsein für die Schwere der Meningokokken-Erkrankung steigt bei Angehörigen medizinischer Berufe und in der breiten Öffentlichkeit, was zu höheren Impfraten beiträgt. Regierungsinitiativen : Viele Länder haben nationale Impfprogramme für Säuglinge, Jugendliche und junge Erwachsene eingeführt, um die Zahl der Meningokokken-Erkrankungen zu senken. Diese Initiativen sind für das Marktwachstum von entscheidender Bedeutung. Fortschritte in der Impfstoffentwicklung : Laufende Fortschritte in der Impfstofftechnologie führen zur Entwicklung wirksamerer Meningokokken-Impfstoffe, die einen umfassenderen Schutz gegen mehrere Stämme bieten und weniger Dosen erfordern. Gesundheitsinfrastruktur : In Ländern mit gut etablierten Gesundheitssystemen, wie den Vereinigten Staaten und dem Vereinigten Königreich, ist ein Trend zu verstärkten Impfungen gegen Meningokokken-Erkrankungen zu verzeichnen. Konjugatimpfstoffe spielen auf dem Meningokokken-Impfstoffmarkt eine entscheidende Rolle, da sie einen wirksamen und lang anhaltenden Schutz gegen Meningokokken-Erkrankungen bieten, die durch das Bakterium Neisseria meningitides verursacht werden. Hier sind die wichtigsten Beiträge von Konjugatimpfstoffen zum Markt: Wichtige Beiträge von Konjugatimpfstoffen Verbesserte Immunogenität : Konjugatimpfstoffe verknüpfen Polysaccharidantigene der Bakterien mit einem Proteinträger, was ihre Immunogenität deutlich erhöht. Dies führt zu einer stärkeren und robusteren Immunantwort im Vergleich zu herkömmlichen Polysaccharidimpfstoffen, insbesondere bei kleinen Kindern, die einem höheren Risiko für Meningokokkenerkrankungen ausgesetzt sind. Langanhaltender Schutz : Diese Impfstoffe induzieren ein immunologisches Gedächtnis, was bedeutet, dass sie einen länger anhaltenden Schutz gegen Meningokokken-Infektionen bieten können. Dies ist besonders wichtig für Bevölkerungsgruppen, die eine anhaltende Immunität benötigen, wie Säuglinge und Kleinkinder Wirksamkeit gegen mehrere Serogruppen : Viele Konjugatimpfstoffe sind so konzipiert, dass sie vor mehreren Serogruppen von Neisseria meningitides schützen , darunter A, C, W und Y. Dieser multivalente Ansatz vereinfacht Impfpläne und erhöht die Gesamtimpfabdeckung, was für die Eindämmung von Ausbrüchen von entscheidender Bedeutung ist. Reduzierung der nasopharyngealen Übertragung : Konjugatimpfstoffe reduzieren nachweislich die nasopharyngeale Übertragung der Bakterien und unterbrechen so die Übertragung innerhalb von Gemeinschaften. Dies trägt zur Herdenimmunität bei und schützt Personen, die möglicherweise nicht geimpft sind. Regierungs- und Gesundheitsinitiativen : Die Einführung von Konjugatimpfstoffen wurde durch verschiedene Regierungsinitiativen und Gesundheitsprogramme unterstützt, die darauf abzielten, die Impfraten zu erhöhen und die Häufigkeit von Meningokokken-Erkrankungen zu verringern. Viele Länder haben diese Impfstoffe in ihre nationalen Impfpläne aufgenommen, da sie ihre Bedeutung bei der Verhinderung von Ausbrüchen erkannt haben. Regionale Analyse des Meningokokken-Impfstoffmarktes Wettbewerbsausblick Das Wettbewerbsumfeld auf dem globalen Markt für Meningokokkenimpfstoffe wird in erster Linie von Innovationen bei der Impfstoffformulierung bestimmt. Die Verbraucherbasis des Unternehmens in der Branche hängt vollständig von der Wirksamkeit, den Kosten und dem Sicherheitsprofil des von ihm entwickelten Impfstoffs ab. Unternehmen arbeiten auch mit Regierungen und internationalen Organisationen zusammen, um ihre Marktreichweite zu erweitern und eine breitere Verfügbarkeit von Impfstoffen sicherzustellen. Einige der bekanntesten Unternehmen der Branche sind GlaxoSmithKline plc, Pfizer Inc., Sanofi Pasteur, Merck & Co., Inc. und Novartis AG. Branchen-Updates Führende Marken für Meningokokken-Impfstoffe MENAFN18122024004107003653ID1109009648 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
